Three hypolipidemic drugs increase hepatic palmitoyl-coenzyme A oxidation in the rat.
Male rats treated with clofibrate, tibric acid, or Wy-14,643 show an 11- to 18-fold increase in the capacity of their livers to oxidize palmitoyl-coenzyme A. This provides a plausible biochemical mechanism for the action of these hypolipidemic drugs in reducing lipid concentrations in the serum.
D000818:Animals; D002374:Catalase / Q000378:metabolism; D002994:Clofibrate / Q000494:pharmacology; D003065:Coenzyme A / Q000378:metabolism*; D003576:Electron Transport Complex IV / Q000378:metabolism; D000960:Hypolipidemic Agents / Q000494:pharmacology*; D008099:Liver / Q000033:anatomy & histology / Q000378:metabolism* / Q000648:ultrastructure; D008297:Male; D008830:Microbodies / Q000201:enzymology; D009929:Organ Size / Q000187:drug effects; D010084:Oxidation-Reduction; D010880:Piperidines / Q000494:pharmacology; D011743:Pyrimidines / Q000494:pharmacology; D051381:Rats; D011916:Rats, Inbred F344; D014992:Xylenes / Q000494:pharmacology
D000960:Hypolipidemic Agents; D010880:Piperidines; D011743:Pyrimidines; D014992:Xylenes; D002374:Catalase; D003576:Electron Transport Complex IV; D002994:Clofibrate; D003065:Coenzyme A